Reducing dose to the lungs through loosing target dose homogeneity requirement for radiotherapy of non small cell lung cancer

被引:9
|
作者
Miao, Junjie
Yan, Hui
Tian, Yuan
Ma, Pan
Liu, Zhiqiang
Li, Minghui
Ren, Wenting
Chen, Jiayun
Zhang, Ye
Dai, Jianrong [1 ]
机构
[1] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Radiat Oncol, Beijing, Peoples R China
来源
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS | 2017年 / 18卷 / 06期
基金
中国国家自然科学基金;
关键词
IMRT; non small cell lung cancer; plan optimization; target dose homogeneity; treatment planning; INTENSITY-MODULATED RADIOTHERAPY; STEREOTACTIC BODY RADIOTHERAPY; TUMOR-CONTROL PROBABILITY; RADIATION PNEUMONITIS; NSCLC PATIENTS; IMRT; VOLUME; THERAPY; DISTRIBUTIONS; PARAMETERS;
D O I
10.1002/acm2.12200
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
It is important to minimize lung dose during intensity-modulated radiation therapy (IMRT) of nonsmall cell lung cancer (NSCLC). In this study, an approach was proposed to reduce lung dose by relaxing the constraint of target dose homogeneity during treatment planning of IMRT. Ten NSCLC patients with lung tumor on the right side were selected. The total dose for planning target volume (PTV) was 60 Gy (2 Gy/fraction). For each patient, two IMRT plans with six beams were created in Pinnacle treatment planning system. The dose homogeneity of target was controlled by constraints on the maximum and uniform doses of target volume. One IMRT plan was made with homogeneous target dose (the resulting target dose was within 95%-107% of the prescribed dose), while another IMRT plan was made with inhomogeneous target dose (the resulting target dose was more than 95% of the prescribed dose). During plan optimization, the dose of cord and heart in two types of IMRT plans were kept nearly the same. The doses of lungs, PTV and organs at risk (OARs) between two types of IMRT plans were compared and analyzed quantitatively. For all patients, the lung dose was decreased in the IMRT plans with inhomogeneous target dose. On average, the mean dose, V5, V20, and V30 of lung were reduced by 1.4 Gy, 4.8%, 3.7%, and 1.7%, respectively, and the dose to normal tissue was also reduced. These reductions in DVH values were all statistically significant (P < 0.05). There were no significant differences between the two IMRT plans on V25, V30, V40, V50 and mean dose for heart. The maximum doses of cords in two type IMRT plans were nearly the same. IMRT plans with inhomogeneous target dose could protect lungs better and may be considered as a choice for treating NSCLC.
引用
收藏
页码:169 / 176
页数:8
相关论文
共 50 条
  • [21] Robust dose-painting-by-numbers vs. nonselective dose escalation for non-small cell lung cancer patients
    Petit, Steven F.
    Breedveld, Sebastiaan
    Unkelbach, Jan
    den Hertog, Dick
    Balvert, Marleen
    MEDICAL PHYSICS, 2021, 48 (06) : 3096 - 3108
  • [22] Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer
    Guckenberger, M.
    Kavanagh, A.
    Partridge, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (10) : 894 - 900
  • [23] Dose-Guided Radiotherapy: Potential Benefit of Online Dose Recalculation for Stereotactic Lung Irradiation in Patients With Non-Small-Cell Lung Cancer
    van Rooijen, Dominique C.
    van Wieringen, Niek
    Stippel, Gjenna
    Crezee, Johannes
    Koning, Caro C. E.
    Bel, Arjan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (04): : E557 - E562
  • [24] Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer
    Lee, Sumin
    Song, Si Yeol
    Kim, Su Ssan
    Choi, Wonsik
    Je, Hyoung Uk
    Back, Geum Mun
    Cho, Byungchul
    Jeong, Seong-Yun
    Choi, Eun Kyung
    CLINICAL LUNG CANCER, 2018, 19 (02) : E253 - E261
  • [25] Radiation dose effect in locally advanced non-small cell lung cancer
    Kong, Feng-Ming
    Zhao, Jing
    Wang, Jingbo
    Faivre-Finn, Corrine
    JOURNAL OF THORACIC DISEASE, 2014, 6 (04) : 336 - 347
  • [26] What radiation dose is safe in patients with non-small-cell lung cancer?
    Larrier, Nicole A.
    Marks, Lawrence B.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (02): : 80 - 81
  • [27] A modified formula for dose calculations of stereotactic ablative body radiotherapy for non-small cell lung cancer
    Cao, Yangsen
    Zhu, Xiaofei
    Zhang, Yu
    Yu, Chunshan
    Liu, Yongming
    Sun, Yongjian
    Dai, Zhitao
    Guo, Xueling
    Ju, Xiaoping
    Zhang, Huojun
    MEDICAL DOSIMETRY, 2018, 43 (03) : 207 - 213
  • [28] Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
    Landman, Yosef
    Jacobi, Oded
    Kurman, Noga
    Yariv, Orly
    Peretz, Idit
    Rotem, Ofer
    Dudnik, Elizabeth
    Zer, Alona
    Allen, Aaron M.
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [29] Concurrent high-dose radiotherapy with low-dose chemotherapy in patients with non-small cell lung cancer of the superior sulcus
    Kappers, Ingrid
    Klomp, Houke M.
    Koolen, Mia G. J.
    Uitterhoeve, Lon J.
    Kloek, Jaap J.
    Belderbos, Jose S. A.
    Burgers, Jacobus A.
    Koning, Caro C. E.
    RADIOTHERAPY AND ONCOLOGY, 2011, 101 (02) : 278 - 283
  • [30] A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer
    Ma, Li
    Men, Yu
    Feng, Lingling
    Kang, Jingjing
    Sun, Xin
    Yuan, Meng
    Jiang, Wei
    Hui, Zhouguang
    RADIOLOGY AND ONCOLOGY, 2019, 53 (01) : 6 - 14